表紙
市場調査レポート

Laboratorios SALVAT S.A. の製品パイプライン分析

Laboratorios SALVAT S.A. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256081
出版日 ページ情報 英文 25 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
Laboratorios SALVAT S.A. の製品パイプライン分析 Laboratorios SALVAT S.A. - Product Pipeline Review - 2015
出版日: 2015年09月30日 ページ情報: 英文 25 Pages
概要

Laboratorios SALVAT S.A. はスペインに本社を置く製薬企業で、パーソナルヘルスケア、代謝性疾患、泌尿器、眼科、皮膚科、マラリアの6分野における製品を40以上の国で取り扱っています。

当レポートでは、Laboratorios SALVAT S.A. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Laboratorios SALVAT S.A. の基本情報

  • Laboratorios SALVAT S.A. の概要
  • 主要情報
  • 企業情報

Laboratorios SALVAT S.A. :R&Dの概要

  • 主な治療範囲

Laboratorios SALVAT S.A. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ

Laboratorios SALVAT S.A. :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Laboratorios SALVAT S.A. :薬剤プロファイル

  • (fluocinolone acetonide + ciprofloxacin hydrochloride)
  • G-238
  • tarafenacin
  • Stem Cell Therapy for Bone Regeneration

Laboratorios SALVAT S.A. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Laboratorios SALVAT S.A. :最新のパイプライン情報

Laboratorios SALVAT S.A. :開発休止中のプロジェクト

Laboratorios SALVAT S.A. :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07625CDB

Summary

Global Markets Direct's, 'Laboratorios SALVAT S.A. - Product Pipeline Review - 2015', provides an overview of the Laboratorios SALVAT S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Laboratorios SALVAT S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Laboratorios SALVAT S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Laboratorios SALVAT S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Laboratorios SALVAT S.A.'s pipeline products

Reasons to buy

  • Evaluate Laboratorios SALVAT S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Laboratorios SALVAT S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Laboratorios SALVAT S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Laboratorios SALVAT S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Laboratorios SALVAT S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Laboratorios SALVAT S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Laboratorios SALVAT S.A. Snapshot
    • Laboratorios SALVAT S.A. Overview
    • Key Information
    • Key Facts
  • Laboratorios SALVAT S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Laboratorios SALVAT S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Laboratorios SALVAT S.A. - Pipeline Products Glance
    • Laboratorios SALVAT S.A. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Laboratorios SALVAT S.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
  • Laboratorios SALVAT S.A. - Drug Profiles
    • (fluocinolone acetonide + ciprofloxacin hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-238
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCSVT-1001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tarafenacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Laboratorios SALVAT S.A. - Pipeline Analysis
    • Laboratorios SALVAT S.A. - Pipeline Products by Target
    • Laboratorios SALVAT S.A. - Pipeline Products by Route of Administration
    • Laboratorios SALVAT S.A. - Pipeline Products by Molecule Type
    • Laboratorios SALVAT S.A. - Pipeline Products by Mechanism of Action
  • Laboratorios SALVAT S.A. - Recent Pipeline Updates
  • Laboratorios SALVAT S.A. - Dormant Projects
  • Laboratorios SALVAT S.A. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Laboratorios SALVAT S.A., Key Information
  • Laboratorios SALVAT S.A., Key Facts
  • Laboratorios SALVAT S.A. - Pipeline by Indication, 2015
  • Laboratorios SALVAT S.A. - Pipeline by Stage of Development, 2015
  • Laboratorios SALVAT S.A. - Monotherapy Products in Pipeline, 2015
  • Laboratorios SALVAT S.A. - Combination Treatment Modalities in Pipeline, 2015
  • Laboratorios SALVAT S.A. - Phase III, 2015
  • Laboratorios SALVAT S.A. - Phase II, 2015
  • Laboratorios SALVAT S.A. - Pipeline by Target, 2015
  • Laboratorios SALVAT S.A. - Pipeline by Route of Administration, 2015
  • Laboratorios SALVAT S.A. - Pipeline by Molecule Type, 2015
  • Laboratorios SALVAT S.A. - Pipeline Products by Mechanism of Action, 2015
  • Laboratorios SALVAT S.A. - Recent Pipeline Updates, 2015
  • Laboratorios SALVAT S.A. - Dormant Developmental Projects,2015
  • Laboratorios SALVAT S.A., Subsidiaries

List of Figures

  • Laboratorios SALVAT S.A. - Pipeline by Top 10 Indication, 2015
  • Laboratorios SALVAT S.A. - Pipeline by Stage of Development, 2015
  • Laboratorios SALVAT S.A. - Monotherapy Products in Pipeline, 2015
  • Laboratorios SALVAT S.A. - Pipeline by Top 10 Target, 2015
  • Laboratorios SALVAT S.A. - Pipeline by Top 10 Route of Administration, 2015
  • Laboratorios SALVAT S.A. - Pipeline by Top 10 Molecule Type, 2015
  • Laboratorios SALVAT S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top